




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68		(11) International Publication Number: WO 98/21361
A1		(43) International Publication Date: 22 May 1998 (22.05.98)
(21) International Application Number: PCT/CA97/00848		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 12 November 1997 (12.11.97)		
(30) Priority Data: 60/031,257 12 November 1996 (12.11.96) US		
(71) Applicant (for all designated States except US): VISIBLE GENETICS INC. [CA/CA]; 700 Bay Street, Box 333, Toronto, Ontario M5G 1Z6 (CA).		
(72) Inventors; and (75) Inventors/Applicants (for US only): DUNN, James, M. [CA/CA]; 117 Citadel Drive, Scarborough, Ontario M1K 2S8 (CA). DIGBY, Thomas, J. [CA/CA]; 388A Sunnyside Avenue, Toronto, Ontario M6R 2S1 (CA).		
(74) Agent: DEETH WILLIAMS WALL; Suite 400, 150 York Street, Toronto, Ontario M5H 3S5 (CA).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: METHOD AND KIT FOR DIRECT ISOTHERMAL SEQUENCING OF NUCLEIC ACIDS

(57) Abstract

Direct determination of the sequence of an RNA sample is performed under isothermal conditions. An RNA sample containing a target nucleic acid is combined in a single reaction vessel with a reaction mixture containing two polynucleotide primers, a first primer that specifically hybridizes with a target sequence near the 3' end of an antisense copy of the target nucleic acid. At least one of the primers is labeled with a detectable label, and at least one of the first or second primers has an RNA polymerase transcription initiation signal at its 5' end, which signal does not specifically hybridize to the RNA target. The reaction mixture also contains ribonucleotide triphosphates for RNA synthesis, deoxyribonucleotide triphosphates for DNA synthesis, at least one type of dideoxynucleotide triphosphate chain-terminator, and enzymes with the activity of reverse transcriptase, RNase H, RNA Polymerase and a low discrimination DNA Polymerase such as Thermo SequenaseTM. The combined reactants are incubated under isothermal conditions for a length of time sufficient to generate chain-terminated reaction products, and the chain-terminated reaction products are then detected after electrophoretic separation.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD AND KIT FOR DIRECT ISOTHERMAL SEQUENCING OF NUCLEIC ACIDS

DESCRIPTION

Background of the Invention

This invention is directed towards a method and kit for determining the nucleotide base sequence of a nucleic acid, particularly for use in routine clinical diagnostic procedures.

DNA sequence-based diagnosis has the potential to become a routine clinical diagnostic test, and is already available in several formats. See, for example, US Patents Nos. 5,545,527, 5,550,020 and 5,552,283 which are incorporated herein by reference. To fully realize the potential for DNA sequence-based diagnostics, however, the development of simplified, and preferably single-tube sequencing techniques will be important.

DNA sequencing techniques are generally well known. Such sequencing is generally performed using techniques based on the "chain termination" method described by Sanger et al., *Proc. Nat'l Acad. Sci. (USA)* 74(12): 5463-5467 (1977). Basically, in this process, DNA to be tested is isolated, rendered single stranded, and placed into four vessels. In each vessel are the necessary components to replicate the DNA strand, i.e., a template-dependant DNA polymerase, a short primer molecule complementary to a known region of the DNA to be sequenced, and individual nucleotide triphosphates in a buffer conducive to hybridization between the primer and the DNA to be sequenced and chain extension of the hybridized primer. In addition, each vessel contains a small quantity of one type of dideoxynucleotide triphosphate, e.g. dideoxyadenosine triphosphate (ddA).

In each vessel, each piece of the isolated DNA is hybridized with a primer. The primers are then extended, one base at a time to form a new nucleic acid polymer complementary to the isolated pieces of DNA. When a dideoxynucleotide is incorporated into the extending polymer, this terminates the polymer strand and prevents it from being further extended. Accordingly, in each vessel, a set of extended polymers of specific lengths are formed which are indicative of the positions of the nucleotide corresponding to the dideoxynucleic acid in that vessel. These sets of polymers are then evaluated using gel electrophoresis to determine the sequence.

Improvements to the original technique described by Sanger et al. have included improvements to the enzyme used to extend the primer chain. For example, Tabor et al. have described enzymes such as T7 DNA polymerase which have increased processivity, and increased levels of incorporation of dideoxynucleotides. (See US Patent No. 4,795,699 and EP-A 655 506, which are incorporated herein by reference). More recently, Reeve et al. have described a thermostable enzyme preparation, called Thermo Sequenase, with many of the properties of T7 DNA polymerase. *Nature* 376: 796-797 (1994). The literature supplied with the Thermo Sequenase product suggests dividing a DNA sample containing 0.5-2 mg of single stranded DNA (or 0.5 to 5 mg of double stranded DNA) into four aliquots, and combining each aliquot with the Thermo Sequenase enzyme preparation, one dideoxynucleotide termination mixture containing one ddNTP and all four dNTP's; and a dye-labeled primer which will hybridize to the DNA to be sequenced. The mixture is placed in a thermocycler and run for 20-30 cycles of annealing, extension and denaturation to produce measurable amounts of dye-labeled extension products of varying lengths which are then evaluated by gel electrophoresis.

DNA sequencing can be performed using these procedures on genomic DNA or cDNA (a DNA copy of mRNA). Alternatively, the direct sequencing of mRNA is known using techniques similar to DNA sequencing.

When low levels of substrate template are present, it is generally necessary to amplify its amount before sequencing reactions can be reliably performed. A well known method of amplifying a DNA strand is by the polymerase chain reaction ("PCR"). PCR methods are disclosed in US Patents Nos. 4,683,194, 4,683,195 and 4,683,202, which are incorporated herein by reference. RNA amplification may be effectively performed using techniques disclosed in US Patents 5,130,238, 5,409,818, 5,554,517 (See also Sooknanan, R., van Gemen, B., and Malek, L.T. "Nucleic Acid Sequence Based Amplification" in Molecular Methods for Virus Detection chp. 12 (Academic Press; 1995)), also incorporated herein by reference. A related RNA amplification method is disclosed by GenProbe patents WO 9101384, WO 9525180, WO 9503430, US 5399491, incorporated herein by reference.

The instant invention discloses a simplified method of determining the sequence of a nucleic acid in a patient sample, in a one-pot or single tube sequencing reaction that does not rely on the PCR method.

It is an object of the invention to provide a method and kit for determining the nucleic acid sequence of an RNA molecule in an RNA sample obtained from a patient sample.

SUMMARY OF THE INVENTION

The method of the invention permits determination of the sequence of nucleotides in a target nucleic acid molecule under isothermal conditions. In accordance with the invention, an RNA sample containing a target nucleic acid is combined in a single reaction vessel with a reaction mixture containing first and second polynucleotide primers, wherein the first primer specifically hybridizes with a target sequence near the 3' end of the target nucleic acid, and the second primer specifically hybridizes to the 3' end of an antisense copy of the target nucleic acid, and wherein at least the first or second primer has a detectable label, and wherein at least one of the first or second primer has an RNA polymerase transcription initiation signal at its 5' end which signal does not specifically hybridize to the RNA target, ribonucleosides ATP, GTP, CTP and UTP or their analogues for RNA synthesis, deoxyribonucleosides dATP, dGTP, dCTP and dTTP or their analogues for DNA synthesis, at least one type of dideoxynucleoside chain terminating nucleoside, or its analogue, and enzymes with the activity of reverse transcriptase, RNase H, RNA Polymerase and ThermoSequenase. The combined reactants are incubated under isothermal conditions for a length of time sufficient to generate chain-terminated reaction products, and the chain terminated reaction products are then detected after electrophoretic separation.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows a first embodiment of the method of the invention schematically;

Fig. 2 shows a second embodiment of the method of the invention schematically; and

Fig. 3 shows a third embodiment of the method of the invention schematically.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a method for determining the nucleic acid sequence of an RNA molecule in an RNA sample obtained from a patient sample. The

RNA molecule may be human or from an animal (particularly mammalian or avian) or may be from a pathogen such as a virus or bacteria which has contaminated the human or animal sample. Suitable patient samples include any tissue, blood, other organs, hair follicles, tumor samples extracted by biopsy or otherwise, or an excretion containing cells such as urine or sputum.

The RNA sample is prepared according to known methods, such as the preferred method for the NASBA reaction disclosed in Sooknanan et al., i.e., by silica pelleting. Care must be taken to prevent the contamination of the sample by the operator or by aerosol contaminants.

In a first embodiment of the invention, the nucleic acid sequence of the RNA molecule (the "target molecule") in the prepared RNA sample is determined by adding the RNA sample to a reaction mixture containing the following components:

(a) First Primer: a polynucleotide primer of 5-50 nt length which is capable of specific hybridization with a target sequence near the 3' end of the target molecule. This primer may be optionally labeled with a first detectable label, such as a fluorescent (e.g. Cy 5.5, FITC etc.) or radioactive moiety. This primer may also optionally have an RNA Polymerase promoter sequence at its 5' end, which sequence does not hybridize specifically with the target molecule.

(b) Second Primer: a polynucleotide primer of 5-50 nt length which is capable of specific hybridization with an anti-sense copy of the target sequence, near the 3' end of the anti-sense molecule. This primer may be optionally labeled with a second detectable label, different from the first detectable label of the first primer, such as a fluorescent or radioactive moiety. This primer may also optionally have an RNA Polymerase promoter sequence at its 5' end, which sequence does not hybridize specifically with the anti-sense copy of the target molecule.

(c) Reverse Transcriptase: a molecule, such as AMV reverse transcriptase (Seikagaku, Rockville, MD), with at least an RNA directed DNA Polymerase activity. This enzyme generates a cDNA copy of an RNA molecule.

(d) RNAse H: an enzyme which selectively degrades RNA in a DNA/RNA hybrid molecule. This activity may be included in the reverse transcriptase enzyme.

(e) Low Discrimination DNA Polymerase: a DNA directed DNA polymerase with a reduced ability to distinguish between dideoxyribonucleotides (ddNTPs) and deoxyribonucleotides (dNTPs), thus tending to incorporate chain-terminating ddNTPs in primer extension reactions. Preferred enzymes incorporate dideoxynucleotides into

an extending nucleic acid polymer at a rate which is no less than about 0.4 times the rate of incorporation of deoxynucleotides. Examples of specific enzymes include ThermoSequenase(TM) (or related enzymes such as Sequenase 2.0) (Amersham Life Sciences, Cleveland, OH). This enzyme need not necessarily be heat stable since it is being used in an isothermal reaction.

(f) RNA Polymerase: an RNA polymerase such as T7 RNA Pol or T3 RNA Pol which recognizes the RNA Pol promoter sequence of the first or second primer.

(g) Ribonucleotide triphosphates (NTPs) and deoxyribonucleotide triphosphates (dNTPs): for nucleotide chain polymer synthesis (4 of each representing nucleotide bases A, C, G and T (or U for RNA)).

(h) At least one chain-terminating dideoxynucleotide triphosphate (ddNTP) for termination of chain extension at a selected base.

The above components are mixed in an appropriate buffer, in appropriate concentrations, to constitute the reaction mixture.

When the RNA sample is mixed with the reaction mixture and incubated, chain-terminated reaction products are formed which can be analyzed to determine the sequence of the initial sample. While not intending to be bound by any particular mechanism, these products are believed to be formed in the steps shown in Fig. 1.

First, as shown in step (a), the first primer hybridizes with the 3' end of the target molecule. Non-specific hybridization is minimized by selection of a suitably high temperature for the reaction (35-65 degrees C). In step (b), primer extension begins with reverse transcriptase using dNTP monomers. Once the chain is extended, (c) the RNase H activity will selectively degrade the original target molecule, leaving a single anti-sense DNA strand. (d) The second primer now hybridizes with the 3' end of the anti-sense DNA strand. Primer extension begins (e) with the DNA directed DNA polymerase, such as ThermoSequenase, and dNTP monomers are incorporated into the extending chain. Simultaneously, if the second primer has the non-hybridizing RNA promoter sequence, a "fill in" chain extension will add additional nucleotides onto the anti-sense DNA.

Because of the presence of the at least one ddNTP, two reaction products may result from the ThermoSequenase reaction. (f) If no ddNTP is incorporated in the nucleotide chain, a full length cDNA may be generated. This reaction product can serve as a template for synthesis of the target molecule by RNA Pol using NTP monomers, given that the second primer has an RNA Pol promoter sequence.

Newly synthesized RNA can then join the reaction sequence at step (a). RNA Pol will produce very large numbers of RNA transcripts under isothermal conditions from a single cDNA (5 to 1000 copies), thus substantially amplifying the amount of target sequence.

The second reaction product (g) is the periodic chain termination product that results from incorporation of a ddNTP. Because the second primer has a detectable label on it, when the reaction products are separated by electrophoresis or otherwise (mass spectrometry, etc.), they can be detected and used for determining nucleotide sequence, in the Sanger et al. method.

It should be noted that even though a chain terminated product has an RNA Pol promoter on it (h), an RNA generated from it will not contain the first primer hybridization site, and will not, therefore, be amplified at the cDNA level.

From this discussion, it is evident that the proper dNTP:ddNTP ratio needs to be ascertained, to generate a suitable amount of full length vs. chain terminated fragments. In the method of the invention, this ratio is determined to fall within the range 1:300 to 5000:1, preferably about 1000:1. The ratio of dNTP to ddNTP is the same for each type of nucleotide, A, C, G or T.

The invention illustrated in Fig. 1 may be further improved by several additional enhancements. One such enhancement is illustrated in Fig. 2. This method relies on the observation that certain reverse transcriptase ("RT") enzymes such as AMV RT and MMLV RT have an inherent RNase H activity (c.f. patent no. EP 408295). This permits the reaction to proceed from step (b) to step (c) in the absence of RNase H itself, as long as the RT has this RNase H activity.

Another enhancement, illustrated in Fig. 3 employs the finding, disclosed in EP 655506, that the ability of a DNA polymerase to distinguish between ddNTPs and dNTPs is influenced by a limited number of amino acids in the active site (ddNTP binding site) of the enzyme. This suggests that a reverse transcriptase could be engineered which has a reduced ability to distinguish between ddNTPs and dNTPs.

Wild type reverse transcriptase incorporates ddNTPs into a chain extending nucleotide rather poorly. For this reason, negligible amounts of ddNTPs are incorporated into the RT reaction (step (b) of Fig. 1), especially if the dNTP: ddNTP ratio is at the preferred concentration of 1000:1.

In fact, wild type reverse transcriptase will incorporate ddNTPs into a chain extending strand at a rate of 1 per 10 to 50 dNTPs, which is somewhat greater

than wild type Taq Polymerase, E. coli DNA Pol I or T4 DNA Pol, where the incorporation rate is less than 1 per 1000. (See Sookan, page 284; or EP 655506). Remarkably, it is found that dideoxy resistant mutant DNA polymerases can be generated by modifying the single amino acid that corresponds to position 526 of T7 DNA Pol, position 762 of E. coli Pol I and 667 of T4 DNA polymerase. Such changes can provide a 250-8000 fold reduction in discrimination levels. Further, modification of at least 13 other sites in the molecule can reduce discrimination although the effect of these alterations is much less, only 5-20 fold.

Dideoxy resistant reverse transcriptase can be generated by site specific mutagenesis techniques. These techniques are well known in the art, (see Sarkar and Sommer 8 Biotechniques 404, 1990) and are explained in detail as they relate to DNA polymerases in EP 655506. Briefly, the technique involves the cloning and expression of mutant forms of a gene encoding a wild type enzyme. Mutations may be introduced either randomly or by site specific techniques. Expressed mutants are then assayed for ddNTP incorporation rates. Presumably, mutations corresponding to the dideoxyresistance mutations observed in other enzymes will be sufficient to create a dideoxy resistant reverse transcriptase. A series of experiments can be performed by anyone skilled in the art which would be reasonably expected to generate a dideoxy-resistant mutant of reverse transcriptase.

With such a non-discriminating RT the method of the invention can be advanced. In Fig. 3 the RT chain extension at step (b) is the source of both the chain terminated fragments and full length fragments. The DNA directed DNA polymerase employed at step (d) is a high fidelity DNA polymerase, which is highly selective against ddNTP incorporation, such as E. Coli DNA Pol I or Taq Polymerase. In this case, the first primer has the detectable label. The RT at step (b) generates chain terminated fragments. Any fragments which are fully extended and not chain terminated are used to generate the second strand of the cDNA (d,e). The RNA template generated in step (f) feeds back into the cycle and can serve as the template for chain termination reactions. This method has the advantage that the RNA is the sequencing template, and it does not need to be converted into cDNA for chain termination reactions. Lower amounts of dNTPs can be usefully employed.

Practice of the method of the present invention can be facilitated by packaging the various enzymes and reagents used in the invention in kit form. For any given target molecule, such a kit includes:

(a) First Primer: a polynucleotide primer of 5-50 nt length which is capable of specific hybridization with a target sequence near the 3' end of the target molecule. This primer may be optionally labeled with a first detectable label, such as a fluorescent (e.g. Cy 5.5, FITC etc.) or radioactive moiety. This primer may also optionally have an RNA Polymerase promoter sequence at its 5' end, which sequence does not hybridize specifically with the target molecule.

(b) Second Primer: a polynucleotide primer of 5-50 nt length which is capable of specific hybridization with an anti-sense copy of the target sequence, near the 3' end of the anti-sense molecule. This primer may be optionally labeled with a second detectable label, different from the first detectable label of the first primer, such as a fluorescent or radioactive moiety. This primer may also optionally have an RNA Polymerase promoter sequence at its 5' end, which sequence does not hybridize specifically with the anti-sense copy of the target molecule.

(c) enzymes providing reverse transcriptase activity, RNase H activity, RNA Polymerase activity and DNA polymerase activity having reduced discrimination between dNTP and ddNTP substrates. The enzymes may be provided in individual packages or as a premixed composition containing all of the enzymes activities.

The kit may further contain Ribonucleosides (NTPs) and deoxyribonucleosides (dNTPs), one or more chain-terminating dideoxynucleoside (ddNTP) for termination of chain extension at a selected base, and appropriate buffers.

The following examples explain how to perform the method of the invention and to achieve its intended results. These examples are not intended to limit the scope of the invention in any way.

Example 1: Preparation of RNA Sample

An RNA sample containing virus HIV-1 is prepared by adding 0.5-1.0 ml sample (serum or plasma) to a 15 ml conical screw cap tube containing 9.0 ml lysis buffer (120 g GuSCN, 2.6 g Triton X-100, 100 ml L2 buffer (12.1 g/l Tris-HCl pH6.4), 22 ml 0.2M EDTA, pH 8.0, final volume 22 ml). Invert tubes to mix. Add 70 ul silica suspension and vortex tube for 5 sec. Leave to 10 min at room temp (18-25 deg. C). Invert every minute to mix. Centrifuge at 1500 g for 2 min. Remove supernatant using a 10 ml plastic pipette, leaving about 0.5 ml residual fluid. Remove residual fluid with sterile pipette without disturbing the pellet. Add 1 ml wash buffer (120 GuSCN, 100 ml L2 buffer) and resuspend silica by vortexing. Transfer silica suspension to a 1.5 ml

microfuge tube. Centrifuge at 10,000 g for 15 sec. Remove supernatant with sterile pipette. Wash the silica pellet four times, one with wash buffer, twice with 70% ethanol and once with acetone.

Dry silica pellet completely by placing the opened tube in a heating block at 56 deg. C for 10 min. Cover the tube with tissue to avoid aerosol contamination. Add 100 ul elution buffer (0.211 g Tris-HCl, pH 8.5/l, sterile) or water and resuspend pellet by vortexing. Incubate at 56 deg. C for 10 min to elute the nucleic acid. Centrifuge at 10,000g for 2 min. Transfer supernatant to a new microfuge tube without disturbing the pellet. Store at -70 deg. C.

Example 2: Direct Isothermal Sequencing

From stock solutions prepare the following reaction mixture in a nuclease free microfuge tube.

Component	Concentration	Volume
buffer	2.5 X	10 ul
Dithiothreitol	250 mM	1 ul
Primer mixture	4 X	6.25 ul
Nuclease-free Water		to 18 ul

buffer 2.5X: 100 mM Tris, pH 8.5, 125 mM KCl, 30 mM MgCl₂, 2.5 mM each dNTP (dATP, dGTP, dCTP, dTTP), 5 mM each NTP (ATP, GTP, CTP, UTP), 10 uM one or more chain terminating dideoxynucleoside (ddATP, ddGTP, ddCTP, ddTTP)

Primer Mixture: 5 pmol first primer, 5 pmol second primer, 3.75 ul 100% DMSO, Water (nuclease free) to 6.25 ul.

First Primer:

5'-AGTGGGGGACATCAAGCAGCCATGCAAA - 3'

SEQ ID No. 1

Second Primer:

5'-AATTCTAATACGACTCACTATAGGG-TGCTATGTCCTTCCCCTTGGTCTCTCA
- 3'

SEQ ID No. 2

These sequences to gag gene mRNA of HIV-1. The second primer is chimeric, the first section being a T7 RNA Polymerase promoter.

The second primer is labeled on its 5' end. The label selected depends on the detection apparatus to be employed. For use with a MicroGene Blaster[®] (Visible Genetics Inc, Toronto, Canada) a suitable label is the fluorescent dye Cy5.5 (Amersham Life Sciences, Cleveland, OH) conjugated to the 5' terminal nucleotide of the primer, by a dye-ester linkage.

Vortex the reaction mixture briefly and aliquot 18 ul into a nuclease free 1.5 ml microfuge tube. Add 5 ul RNA sample and mix by tapping. Incubate at 65 deg. C for 5 min. Transfer to a 40 ± 1 deg. C water bath, and equilibrate for 5 mins.

Add 2 ul Enzyme Mixture* to the reaction tubes and gently mix by tapping. Centrifuge at 10,000 g for 5 sec. Incubate at 40 ± 1 deg. C for 90 mins. Centrifuge briefly to collect condensate. Place on ice until ready for loading.

* Enzyme Mixture - 0.13 ul 20 mg/ml BSA (in 50% glycerol; Boehringer Mannheim), 8 U AMV reverse transcriptase (Seikagaku), 0.2 U E. coli RNase H (Pharmacia), 40 U T7 RNA Polymerase (Pharmacia) and 3 U ThermoSequenase (Amersham Life Sciences, Cleveland, OH).

When ready for loading and observing detectable reaction products, the reaction products are mixed with an equal volume of STOP/Loading buffer (Formamide, colored dye) and mixed well. 1.5 ul of the resulting mix is loaded per lane of a MicroGel[®] gel electrophoresis cassette loaded in a MicroGene Blaster[®] DNA sequencer. The sample is electrophoresed and detected by the automated laser detection system. Results are stored in a computer and analyzed by GeneObjects[®] Software (Visible Genetics Inc., Toronto, Canada).

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Visible Genetics Inc.

Dunn, James M.

Digby, Thomas J.

(ii) TITLE OF INVENTION: Method and Kit for Direct Isothermal Sequencing of Nucleic Acids

(iii) NUMBER OF SEQUENCES: 2

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE:

(B) STREET:

(C) CITY:

(D) STATE:

(E) COUNTRY:

(F) ZIP:

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE:

(B) COMPUTER:

(C) OPERATING SYSTEM:

(D) SOFTWARE:

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME:

(B) REGISTRATION NUMBER:

(C) REFERENCE/DOCKET NUMBER:

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE:

(B) TELEFAX:

(C) TELEX:

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: HIV-1

(ix) FEATURE:

(D) OTHER INFORMATION: sequencing primer for gag gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
AGTGGGGGGA CATCAAGCAG CCATGCAAA 29

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 55

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: HIV-1

(ix) FEATURE:

(D) OTHER INFORMATION: sequencing primer for gag gene with RNA polymerase promoter

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

AATTCTAATA CGACTCACTA TAGGGTGCT ATGTCCTTC CCCTTGGTTC TCTCA
55

CLAIMS

1. A method of determining the sequence of nucleotides in a target nucleic acid under isothermal conditions comprising the steps of:

(a) combining in a single reaction vessel

an RNA sample containing a target nucleic acid,

first and second polynucleotide primers, wherein the first primer specifically hybridizes with a target sequence near the 3' end of the target nucleic acid, and the second primer specifically hybridizes to the 3' end of an antisense copy of the target nucleic acid, and wherein at least the first or second primer has a detectable label, and wherein at least one of the first or second primer has an RNA polymerase transcription initiation signal at its 5' end which signal does not specifically hybridize to the RNA target,

ribonucleotide triphosphates for RNA synthesis,

deoxyribonucleotide triphosphates for DNA synthesis,

at least one type of chain terminating nucleotide triphosphate,

and enzymes with the activity of reverse transcriptase, RNase H,

RNA Polymerase and a low discrimination DNA Polymerase;

(b) incubating the combined reactants under isothermal conditions for a length of time sufficient to generate chain-terminated reaction products, and


(c) detecting chain terminated reaction products after electrophoretic separation, said chain terminated reaction products reflecting the sequence of nucleotides in the target nucleic acid.

2. The method of claim 1, wherein the low discrimination DNA polymerase incorporates dideoxynucleotides into an extending nucleic acid polymer at a rate which is no less than about 0.4 times the rate of incorporation of deoxynucleotides.

3. The method according to claim 1 or 2, wherein at least one enzyme having both reverse transcriptase and RNase H activity is included in the reaction mixture.

4. The method according to claim 3, wherein the enzyme having both reverse transcriptase and RNase H activity is included in the reaction mixture is selected from among AMV reverse transcriptase and MMLV reverse transcriptase.
5. The method according to any of claims 1 to 4, wherein the deoxynucleotide triphosphates and the chain terminating nucleotide triphosphate are present in a mole ratio of from 1:300 to 5000:1.
6. A kit for isothermal sequencing of a target RNA molecule comprising, in packaged combination,
- (a) a first polynucleotide primer of 5-50 nt length which is capable of specific hybridization with a target sequence near the 3' end of the target RNA molecule
 - (b) a second polynucleotide primer of 5-50 nt length which is capable of specific hybridization with an anti-sense copy of the target RNA molecule; and
 - (c) enzymes sufficient to provide reverse transcriptase activity, RNase H activity, RNA Polymerase activity and low discrimination DNA polymerase activity having reduced discrimination between dNTP and ddNTP substrates, wherein at least one of the first and second primers is labeled with a detectable label and wherein at least one of the first and second primers includes an RNA polymerase initiation signal at the 5'-end thereof, which signal does not specifically hybridize with the target RNA molecule.
7. The kit according to claim 6, wherein the low discrimination DNA polymerase incorporates dideoxynucleotides into an extending nucleic acid polymer at a rate which is no less than about 0.4 times the rate of incorporation of deoxynucleotides.
8. The kit according to claim 6 or 7, wherein at least one enzyme having both reverse transcriptase and RNase H activity is included in the kit.
9. The kit according to any of claims 6 to 8, wherein at least one of the first or second primers is labeled with a fluorescent label.

1/3






FIG. 3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 97/00848

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12Q1/68

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	AXELROD V D ET AL: "TRANSCRIPTION FROM BACTERIOPHAGE T7 AND SP6 RNA POLYMERASE PROMOTERS IN PRESENCE OF 3'-DEOXYRIBONUCLEOSIDE 5'-TRIPHOSPHATE CHAIN TERMINATORS" BIOCHEMISTRY, vol. 24, no. 21, October 1985, pages 5716-5723, XP000674402 see the whole document ---	1-9
Y	KLEMENT J F ET AL: "SEQUENCING OF DNA USING T3 RNA POLYMERASE AND CHAIN TERMINATING RIBONUCLEOTIDE ANALOGS" GENE ANALYSIS TECHNIQUES, vol. 3, no. 4, July 1986, pages 59-66, XP000674971 see the whole document ---	1-9

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

3 March 1998

Date of mailing of the international search report

10/03/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 3402040, Tx. 31 651 epo nl,
Fax: (+31-70) 3403016

Authorized officer

Osborne, H

INTERNATIONAL SEARCH REPORT

Inter nal Application No

PCT/CA 97/00848

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>PARVIN J D ET AL: "RAPID RNA SEQUENCING USING DOUBLE-STRANDED TEMPLATE DNA, SP6 POLYMERASE, AND 3'DEOXYNUCLEOTIDE TRIPHOSPHATES"</p> <p>DNA, vol. 5, no. 2, April 1986, pages 167-171, XP000674970 see the whole document</p> <p style="text-align: center;">----</p>	1-9
Y	<p>WO 96 14434 A (INST OF PHYSICAL AND CHEMICAL ;HAYASHIZAKI YOSHIHIDE (JP); SASAKI) 17 May 1996 see the whole document</p> <p style="text-align: center;">----</p>	1-9
Y	<p>WO 96 02668 A (CANGENE CORP ;SOOKNANAN, ROY (CA)) 1 February 1996 see the whole document</p> <p style="text-align: center;">----</p>	1-9
Y	<p>WO 89 01749 A (OSWALD KURT) 9 March 1989 see the whole document</p> <p style="text-align: center;">-----</p>	1-9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 97/00848

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9614434 A	17-05-96	CA 2204378 A EP 0785278 A	17-05-96 23-07-97
WO 9602668 A	01-02-96	AU 3336695 A CA 2195209 A EP 0776376 A	16-02-96 01-02-96 04-06-97
WO 8901749 A	09-03-89	DE 3728408 A EP 0335921 A JP 2501119 T US 5060326 A	09-03-89 11-10-89 19-04-90 29-10-91